Riskpilot← Back to searchSign inGet full accessPharma Office Sverige AB
ABActiveOrg 5593983413Tullvaktsvägen 2Beauty care and other beauty treatment activities · NACE 9622Est. 20220 employees
Revenue 2025
SEK 34K
+1% vs 2024
EBITDA margin
-41.2%
-39% vs 2024
Equity ratio
-398.6%
Financial strength
Net profit 2025
SEK -14K
-41% vs 2024
| Revenue | SEK 34K | +1% |
| EBITDA | SEK -14K | -39% |
| Net profit | SEK -14K | -41% |
| Total assets | SEK 1K | -92% |
| Equity | SEK -6K | -164% |
| Employees | 0 | — |
Legal name
Pharma Office Sverige AB
Org number
5593983413
Legal form
Aktiebolag
NACE code
9622 · Beauty care and other beauty treatment activities
Founded
22 september 2022
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva handel och försäljning av apoteksnära handelsvaror, egenvårdsprodukter såsom hudvård, hälsokost, medicinsktekniska produkter samt därmed förenlig verksamheten.
Address
Tullvaktsvägen 2
Email
a.bjurmar@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 16 | 34 | 34 |
| Staff expenses | — | — | — |
| EBITDA | −6 | −10 | −14 |
| Depreciation & amort. | — | — | — |
| EBIT | −6 | −10 | −14 |
| Net financials | 0 | 0 | −0 |
| Profit before tax | −6 | −10 | −14 |
| Tax | — | — | — |
| Net profit | −6 | −10 | −14 |
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 25 | 18 | 1 |
| Equity | 19 | 9 | −6 |
| Long-term debt | — | — | — |
| Short-term debt | 6 | 10 | 7 |
| Total debt | 6 | 10 | 7 |
EBITDA margin
-41.2%
This company
15.8%
Market median
-361% vs market
20232025
Equity ratio
-398.6%
This company
38.2%
Market median
-1143% vs market
20232025
Return on equity
-1416500.0%
This company
18.4%
Market median
-7698470% vs market
20232025
Net profit margin
-41.3%
This company
8.1%
Market median
-610% vs market
20232025
Asset turnover
24.65×
This company
1.12×
Market median
+2101% vs market
20232025
Debt / equity
1.25×
This company
0.62×
Market median
-102% vs market
20232025
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
ED Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Chairman | 2022 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharma Office Sverige AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Dogra | Deputy Chief Executive Officer | 0 companies |
| Mikko Penttilä | Chairman | 0 companies |
| Anders Johan Erik Bjurmar | Chairman | 0 companies |
| Mika Samuli Kekkonen | Board of Directors | 0 companies |
| Heli Katriina Penttilä | Board of Directors | 0 companies |